Retatrutide vs Zepbound: Which Works Better?
No one can name a winner yet. A direct trial is comparing retatrutide with tirzepatide, the ingredient in Zepbound, but it has not reported results. For care available today, their FDA status is the clearest difference: Zepbound is approved; retatrutide is investigational.
LiveNow Longevity ·
The comparison right now
Available under an FDA-approved label
Zepbound
Tirzepatide activates GIP and GLP-1 receptors. FDA approved Zepbound for chronic weight management in eligible adults, alongside diet and physical activity. Its label defines uses, contraindications and warnings.
Investigational
Retatrutide
Retatrutide targets GIP, GLP-1 and glucagon receptors. Lilly has reported results from separate Phase 3 trials and plans to seek FDA review, but retatrutide is not approved for treatment.
These are regulatory and study-status facts, not a ranking of effectiveness. FDA's Zepbound approval, retatrutide warning and Lilly update support them.
Why the percentages do not pick a winner
Lilly has announced weight-loss results for retatrutide in Phase 3 studies. Zepbound has its own clinical evidence and FDA-approved label. Putting a result from one study next to a result from another can be tempting, but the participants, doses, outcome definitions and study duration may differ. That calculation cannot establish which medicine would work better for the same person.
What would answer the question? A direct randomized comparison with reported results, considered alongside safety, tolerability and the people studied. TRIUMPH-5 was designed to provide that comparison; it has not yet done so publicly.
What TRIUMPH-5 is testing
The registered Phase 3 TRIUMPH-5 study, NCT06662383, randomizes adults with obesity to retatrutide or tirzepatide and measures percent change in body weight at week 80. Its current status is “active, not recruiting.” The estimated primary completion is November 2026, and the registry has no posted results as of this page's update.
Primary completion means the planned point for collecting the primary outcome. It does not promise when full data will be analyzed, published or reviewed by FDA. We will update this answer when a verifiable head-to-head result is available.
What this means if you are deciding on care now
Retatrutide is not an FDA-approved prescription option, and FDA states that it cannot be used in compounding under federal law. A research-use product sold online is not a substitute for an approved medication or enrollment in a supervised study. LiveNow does not offer retatrutide treatment or a retatrutide waitlist.
If you want to discuss presently available weight-management care, an individual evaluation can address eligibility, label warnings, other conditions, cost and follow-up. An evaluation does not guarantee Zepbound or any other prescription. See our medical weight-management information and retatrutide FDA-status guide.
Common questions
Has retatrutide beaten Zepbound in a head-to-head trial?
No head-to-head result has been reported. TRIUMPH-5 directly compares retatrutide with tirzepatide, the active ingredient in Zepbound, but the ClinicalTrials.gov record lists no results as of September 25, 2026.
Why do some headlines say retatrutide causes more weight loss?
They often place percentages from separate studies side by side. Those studies enrolled different populations and used different designs, doses and follow-up periods. That is not a reliable comparison of the medicines.
Is retatrutide FDA-approved like Zepbound?
No. Zepbound is an FDA-approved tirzepatide product with specific labeled uses. Retatrutide remains investigational, and FDA says it cannot be used in compounding under federal law.
When will the comparison trial report results?
The TRIUMPH-5 registry lists an estimated primary completion in November 2026. That estimate is not a guaranteed results publication date or an FDA approval date.
Public regulatory and trial sources checked September 25, 2026. This guide is educational information, not individual medical advice.